FARAPULSE™
Pulsed Field Ablation System
FARAPULSE™ Pulsed Field Ablation System, the world's clinical leader in PFA used in 125,000+ patients, is transforming treatment for atrial fibrillation by:
- Selectively ablating myocardium to reduce risk of damage to surrounding tissue
- Delivering durable transmural pulmonary vein (PV) lesions to limit redo procedures for PV triggers
- Adapting to variable patient PV anatomy for reproducible procedures and limiting left atrium (LA) dwell time
- Creating workflow efficiencies to simplify the procedure and shorten the learning curve
- Visualizing workflow with integrated mapping and a magnetically-tracked catheter
Key Resources
Transformative possibilities for AFib treatment
Tissue-selective ablation
FARAPULSE restricts therapy to only the intended target.
- ADVENT Pivotal Trial: FARAPULSE met all primary endpoints for safety and efficacy1 (posterior probability >0.999)
- MANIFEST-17K Registry (17,000+ pts): no reported esophageal fistula, permanent phrenic nerve palsy, and pulmonary vein stenosis.2
Optimized for efficacy
FARAPULSE offers a proven dosing strategy that delivers durable lesions.
- Delivers durable lesions via streamlined workflow using multiple distal shapes in a single catheter
- Propensity-Matched Study: PV reconnection rate significantly lower for FARAPULSE vs. CBA and RFA.3
Rapid and reproducible
The FARAPULSE workflow is rapid and reproducible, while reducing procedural duration variability.
- EU-PORIA Multicenter Registry: consistent FARAPULSE procedure times, even among operators with varied experience.4
- PFA ablation time significantly lower, with an average reduction of 42% vs. thermal ablation.1
Mapping experience
FARAPULSE innovation continues with the mapping integration of the FARAVIEW™ Software Module and the FARAWAVE™ NAV Pulsed Field Ablation Catheter.
Together, they allow operators to confirm ablation success while maintaining worfklow simplicity. FARAVIEW is available exclusively on the OPAL HDx™ Mapping System.
System components
Explore VersaCross Connect >
References:
1. Reddy VY, Gerstenfeld EP, Natale A, et al., Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. New England Journal of Medicine. 2023;Nov2;389(18):1660-1671. doi:10.1056/NEJMoa2307291
2. Ekanem, E., Neuzil, P., Reichlin, T. et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med (2024). https://doi.org/10.1038/s41591-024-03114-3
3. Della Rocca DG, Marcon L, Magnocavallo M, et al., Pulsed electric field, cryoballoon, and radiofrequency for paroxysmal atrial fibrillation ablation: a propensity score-matched comparison, EP Europace, 2024;Jan26(1) euae016. doi.org/10.1093/europace/euae016
4. Schmidt B, Bordignon S, Neven K, et al., EUropean real-world outcomes with Pulsed field ablation in patients with symptomatic atrial fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023;25(7):euad185. doi:10.1093/europace/euad185